OBJECTIVES: Papillary renal cell carcinoma (pRCC) represents the largest subgroup of non-clear-cell kidney cancer. In this study, we assessed tumour characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC). METHODS: We evaluated 744 patients who had undergone renal surgery for RCC between 1990 and 2005. The mean follow-up was 5.6 years, the patients being followed-up until December 2007. RESULTS: Both groups, pRCC and ccRCC, were alike concerning age, body mass index, and the incidence of regional lymph node or distant metastasis at diagnosis. The percentage of male patients was higher in pRCC than in ccRCC (73.8 vs. 60.3%, p = 0.006). Even though patients with pRCC presented more often with smaller (p = 0.039) and low-grade tumours (p = 0.006), there was no statistically significant difference in tumour recurrence or tumour related death. Kaplan-Meier curves revealed no differences regarding tumour specific survival between pRCC and ccRCC (p = 0.94; 5-year survival 78 vs. 77%). CONCLUSIONS: Even though pRCC and ccRCC differ significantly in many aspects including histology and genetic alterations, their long term prognosis is comparable. As we could not confirm a favourable clinical course for pRCC in general, standardised aftercare programmes and-if necessary-systemic treatment, especially in the era of novel targeted drugs, are also needed for this common RCC subtype.
OBJECTIVES:Papillary renal cell carcinoma (pRCC) represents the largest subgroup of non-clear-cell kidney cancer. In this study, we assessed tumour characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC). METHODS: We evaluated 744 patients who had undergone renal surgery for RCC between 1990 and 2005. The mean follow-up was 5.6 years, the patients being followed-up until December 2007. RESULTS: Both groups, pRCC and ccRCC, were alike concerning age, body mass index, and the incidence of regional lymph node or distant metastasis at diagnosis. The percentage of male patients was higher in pRCC than in ccRCC (73.8 vs. 60.3%, p = 0.006). Even though patients with pRCC presented more often with smaller (p = 0.039) and low-grade tumours (p = 0.006), there was no statistically significant difference in tumour recurrence or tumour related death. Kaplan-Meier curves revealed no differences regarding tumour specific survival between pRCC and ccRCC (p = 0.94; 5-year survival 78 vs. 77%). CONCLUSIONS: Even though pRCC and ccRCC differ significantly in many aspects including histology and genetic alterations, their long term prognosis is comparable. As we could not confirm a favourable clinical course for pRCC in general, standardised aftercare programmes and-if necessary-systemic treatment, especially in the era of novel targeted drugs, are also needed for this common RCC subtype.
Authors: Ximing J Yang; Min-Han Tan; Hyung L Kim; Jonathon A Ditlev; Mark W Betten; Carolina E Png; Eric J Kort; Kunihiko Futami; Kyle A Furge; Masayuki Takahashi; Hiro-Omi Kanayama; Puay Hoon Tan; Bin Sing Teh; Chunyan Luan; Kim Wang; Michael Pins; Maria Tretiakova; John Anema; Richard Kahnoski; Theresa Nicol; Walter Stadler; Nicholas G Vogelzang; Robert Amato; David Seligson; Robert Figlin; Arie Belldegrun; Craig G Rogers; Bin Tean Teh Journal: Cancer Res Date: 2005-07-01 Impact factor: 12.701
Authors: S Störkel; J N Eble; K Adlakha; M Amin; M L Blute; D G Bostwick; M Darson; B Delahunt; K Iczkowski Journal: Cancer Date: 1997-09-01 Impact factor: 6.860
Authors: L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar Journal: Nat Genet Date: 1997-05 Impact factor: 38.330
Authors: W Marston Linehan; James Vasselli; Ramaprasad Srinivasan; McClellan M Walther; Maria Merino; Peter Choyke; Cathy Vocke; Laura Schmidt; Jennifer S Isaacs; Gladys Glenn; Jorge Toro; Berton Zbar; Donald Bottaro; Len Neckers Journal: Clin Cancer Res Date: 2004-09-15 Impact factor: 12.531
Authors: S Waalkes; F C Roos; H Eggers; S Schumacher; M Janssen; G Wegener; J W Thüroff; R Hofmann; M Schrader; M A Kuczyk; A J Schrader Journal: Urologe A Date: 2011-09 Impact factor: 0.639
Authors: Andrew B Rosenkrantz; Aarti Sekhar; Elizabeth M Genega; Jonathan Melamed; James S Babb; Amish D Patel; Andy Lo; Robert M Najarian; Muneeb Ahmed; Ivan Pedrosa Journal: Eur Radiol Date: 2012-08-21 Impact factor: 5.315
Authors: Sandra Waalkes; Faranaz Atschekzei; Mario W Kramer; Jörg Hennenlotter; Gesa Vetter; Jan U Becker; Arnulf Stenzl; Axel S Merseburger; Andres J Schrader; Markus A Kuczyk; Jürgen Serth Journal: BMC Cancer Date: 2010-09-22 Impact factor: 4.430